Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$119.79 USD

119.79
2,009,823

+0.19 (0.16%)

Updated Dec 1, 2021 04:05 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
2Buy19.05%
3Hold10.68%
4Sell6.41%
5Strong Sell3.08%
S&P50011.42%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (181 out of 254)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

MedTech Long-Term Prospects Impress: Which Stocks to Buy?

President Trump will finally replace the ACA and implement his own strategy, the nation is clearly divided into "we need" and "don't need" camps.

    Zimmer Biomet (ZBH): Tops Q4 Earnings Estimates, Meets Sales

    Zimmer Biomet (ZBH) has posted mixed results with its earnings surpassing the Zacks Consensus Estimate and revenues in line with the mark.

      Medical Products Stocks' Earnings on Jan 31: ZBH, TMO, ABC

      Let's take a look at the major Medical Product stocks slated to release their earnings results on tomorrow.

        Zimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?

        Zimmer Biomet Holdings, Inc. (ZBH) is expected to report fourth-quarter 2017 financial numbers on Jan 31, before the opening bell.

          Does Zimmer Biomet Make for a Suitable Value Investment?

          The solid Key Value Statistics are likely to make Zimmer Biomet (ZBH) a decent pick for the value investors.

            Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical

            Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical

              Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

              Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche

                MedTech Sails Through Macro Woes: Stocks in Focus

                Mergers & acquisitions, emerging market expansion, positive demographic trends and new product innovation are the vital forces behind the continued uptrend in the sector's performance.

                  MedTech Industry Stock Outlook - December 2016

                  The Republican win marked a great victory for the entire medical device industry as the likelihood of a permanent repeal of the 2.3% medical device excise tax will come as a big bonus.

                    MedTech Industry Stock Outlook - Dec. 2015

                    While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.

                      MedTech Industry Stock Outlook - Dec. 2015

                      While the global economy has been on a rollercoaster ride over the past quarter, the MedTech sector has not only held its own, but maintained a stable uptrend.

                        3 MedTech Stocks Poised to Trump Earnings in Q3

                        Positive demographic trends, new product cycles, expansion into emerging markets and widespread consolidation are the key traits for the MedTech sector.

                          MedTech Industry Stock Outlook - July/Aug 2015

                          Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.

                            MedTech Industry Stock Outlook - July/Aug 2015

                            Recently released government data showed that about 16.4 million uninsured people have gained health insurance coverage since the enactment of the Affordable Care Act five years back.

                              MedTech M&As Continue Regardless of Tax Scenarios

                              MedTech stalwarts are not expected to shy away from hostile acquisition bids this year.